Back to Search Start Over

Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.

Authors :
Connolly S
Alcaraz L
Bailey A
Cadogan E
Christie J
Cook AR
Fisher AJ
Hill S
Humphries A
Ingall AH
Kane Z
Paine S
Pairaudeau G
Stocks MJ
Young A
Source :
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2011 Aug 01; Vol. 21 (15), pp. 4612-6. Date of Electronic Publication: 2011 Jun 13.
Publication Year :
2011

Abstract

Starting with the molecular scaffold of the DA(2)/β(2) dual agonist sibenadet (Viozan™), a number of molecular changes were incorporated, which were designed to increase the potency and selectivity of the target molecule, and improve its pharmacokinetics. Through this process a novel, high potency, full β(2)-agonist with high selectivity and long duration capable of being dosed once daily has been discovered.<br /> (Copyright © 2011. Published by Elsevier Ltd.)

Details

Language :
English
ISSN :
1464-3405
Volume :
21
Issue :
15
Database :
MEDLINE
Journal :
Bioorganic & medicinal chemistry letters
Publication Type :
Academic Journal
Accession number :
21723724
Full Text :
https://doi.org/10.1016/j.bmcl.2011.05.097